Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse

Takayuki Yoshimoto; Izuru Mizoguchi; Seiichiro Katagiri; Tetsuzo Tauchi; Jun-Ichi Furusawa; Yukino Chiba; Junichiro Mizuguchi; Junko H Ohyashiki; Kazuma Ohyashiki

doi:10.4161/onci.28861

Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse

Oncoimmunology. 2014 May 14:3:e28861. doi: 10.4161/onci.28861. eCollection 2014.

Authors

Takayuki Yoshimoto¹, Izuru Mizoguchi¹, Seiichiro Katagiri², Tetsuzo Tauchi², Jun-Ichi Furusawa¹, Yukino Chiba³, Junichiro Mizuguchi⁴, Junko H Ohyashiki⁵, Kazuma Ohyashiki²

Affiliations

¹ Department of Immunoregulation; Institute of Medical Science; Tokyo Medical University; Tokyo, Japan.
² Department of Hematology; Tokyo Medical University; Tokyo, Japan.
³ Department of Immunoregulation; Institute of Medical Science; Tokyo Medical University; Tokyo, Japan ; Department of Immunology; Tokyo Medical University; Tokyo, Japan.
⁴ Department of Immunology; Tokyo Medical University; Tokyo, Japan.
⁵ Department of Molecular Oncology; Institute of Medical Science; Tokyo Medical University; Tokyo, Japan.

Abstract

Tyrosine kinase inhibitors have dramatically improved the treatment of chronic myeloid leukemia. Recent evidence revealed that some patients with chronic myeloid leukemia can stop imatinib without relapse after achieving a complete molecular response. This review discusses the possible predictive markers to identify these patients who can stop imatinib without relapse.

Keywords: NK cells; chronic myeloid leukemia; cytotoxic T lymphocytes; imatinib; immunosurvelliance; predictive marker.

Publication types

Research Support, Non-U.S. Gov't